Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
16.16
-0.15 (-0.95%)
Jul 28, 2026, 4:00 PM EDT - Market closed
Rallybio Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 41.3 | 31.37 | 13.9 | 24.49 | 56.96 | 175.33 |
Short-Term Investments | 5.5 | 23.36 | 51.61 | 85.44 | 112.04 | - |
Cash & Short-Term Investments | 46.8 | 54.74 | 65.51 | 109.93 | 168.99 | 175.33 |
Cash Growth | -14.13% | -16.45% | -40.41% | -34.95% | -3.62% | 25.03% |
Other Current Assets | 6.7 | 6.52 | 2.33 | 4.86 | 10.5 | 5.54 |
Total Current Assets | 53.49 | 61.25 | 67.84 | 114.79 | 179.5 | 180.87 |
Net Property, Plant & Equipment | 0.17 | 0.2 | 0.27 | 0.59 | 0.91 | 0.51 |
Long-Term Investments | - | - | - | 0.24 | 0.03 | 0.81 |
Other Long-Term Assets | 0.81 | 0.81 | - | - | - | - |
Total Assets | 54.47 | 62.26 | 68.11 | 115.62 | 180.44 | 182.19 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.94 | 0.13 | 0.28 | 0.98 | 1.11 | 0.6 |
Accrued Expenses | 3.1 | 3.79 | 4.96 | 8.07 | 9.45 | 5.95 |
Current Portion of Leases | 0.1 | 0.09 | 0.15 | 0.22 | 0.18 | - |
Unearned Revenue | - | 0.21 | 0.85 | - | - | - |
Total Current Liabilities | 4.14 | 4.22 | 6.24 | 9.26 | 10.74 | 6.55 |
Long-Term Leases | 0.06 | 0.08 | - | 0.17 | 0.37 | - |
Other Long-Term Liabilities | - | - | 0.21 | - | - | 0.03 |
Total Long-Term Liabilities | 0.06 | 0.08 | 0.21 | 0.17 | 0.37 | 0.03 |
Total Liabilities | 4.2 | 4.31 | 6.45 | 9.44 | 11.12 | 6.58 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-in Capital | 360.55 | 359.93 | 354.6 | 341.41 | 330.21 | 269.63 |
Accumulated Other Comprehensive Income | 0 | 0.02 | 0.07 | 0.02 | -0.21 | - |
Retained Earnings | -310.28 | -302 | -293.02 | -235.25 | -160.68 | -94.03 |
Shareholders' Equity | 50.28 | 57.96 | 61.65 | 106.18 | 169.32 | 175.6 |
Total Liabilities & Equity | 54.47 | 62.26 | 68.11 | 115.62 | 180.44 | 182.19 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.15 | 0.18 | 0.15 | 0.39 | 0.56 | 0 |
Net Cash (Debt) | 46.64 | 54.56 | 65.36 | 109.54 | 168.44 | 175.33 |
Net Cash Growth | -14.23% | -16.52% | -40.33% | -34.97% | -3.93% | 25.03% |
Net Cash Per Share | 8.25 | 9.69 | 12.01 | 21.66 | 42.35 | 54.97 |
Book Value | 50.28 | 57.96 | 61.65 | 106.18 | 169.32 | 175.6 |
Book Value Per Share | 8.90 | 10.30 | 11.33 | 21.00 | 42.57 | 55.05 |
Tangible Book Value | 50.28 | 57.96 | 61.65 | 106.18 | 169.32 | 175.6 |
Tangible Book Value Per Share | 8.90 | 10.30 | 11.33 | 21.00 | 42.57 | 55.05 |